- Expanding 라이브 바카라 client engagement through presentations and business meetings
- Meeting customer needs with a comprehensive full-cycle 라이브 바카라 solution from early development to IND
[by Ji, Yong Jun] Samsung Biologics announced on May 13 that it participated in the ‘Protein & Antibody Engineering Summit (PEGS) Boston,’ a leading global biopharmaceutical technology conference. At the event, the company showcased its contract development (CDO) capabilities, highlighting its expertise in high-concentration formulation drug development and the evaluation of candidate substance development potential.
‘PEGS Boston’ is the world’s largest conference dedicated to protein and antibody pharmaceuticals, attracting over 2,400 participants to discuss the latest advances in biopharmaceutical technology. Held annually each May in Boston, Massachusetts, the 2025 conference will run for five days from May 12 to 16 (local time). At this year’s event, 라이브 바카라 Biologics focused on expanding its contact points with major customers by setting up a dedicated meeting space and conducting business meetings with major global pharmaceutical companies.
On the first day of the conference, May 12th, 라이브 바카라 Biologics held a lunch presentation titled ‘Streamlining Drug Development: From Developability Assessment to High-Concentration Formulation Development,’ showcasing its advanced CDO technologies. Lim Heon-chang, Director of the Formulation Development Group at the CDO Development Center, introduced the company’s core CDO services, including ‘S-HiCon,’ a high-concentration formulation drug development platform, and ‘DEVELOPICK,’ a platform for assessing development potential.
S-HiCon is a platform introduced by 라이브 바카라 Biologics in October 2024, leveraging the company’s extensive experience in formulation development to support clients in creating ‘ultra-high concentration’ drug formulations. According to the company, high-concentration formulations offer advantages over conventional low-concentration drugs, including reduced patient medication burden and lower storage and transportation costs, leading to a growing demand in the market.
DEVELOPICK is a 라이브 바카라 feasibility assessment platform that has undergone continuous upgrades since its initial launch in October 2022, now reaching version 3.0. It is designed to identify the optimal candidate substance in the early stages of new drug discovery by evaluating the properties of the substance using only a small amount of protein.
라이브 바카라 Biologics has established a comprehensive technology platform encompassing nine types of CDO services, tailored to meet the diverse needs of its clients. In addition to S-HiCon and DEVELOPICK, the company offers a full range of customized CDO solutions, from early-stage development to clinical trial planning (IND), including its proprietary cell line platform ‘S-CHOice,’ dual antibody platform ‘S-DUAL,’ candidate substance rapid expression platform ‘S-CHOsient,’ analysis-based substance support platform ‘S-Glyn,’ high-concentration biopharmaceutical development support platform ‘S-Tensify,’ afucosylated cell line platform ‘S-AfuCHO,’ and protein charge mutation control platform ‘S-Opticharge.’
Meanwhile, 라이브 바카라 Biologics has been actively participating in various global conferences this year to broaden its network with existing and prospective global clients. In January, the company engaged with numerous clients at the ‘JP Morgan Healthcare Conference (JPMHC),’ followed by ‘DCAT Week’ in March. Looking ahead, the company plans to further intensify its order-winning efforts by participating in the ‘2025 BIO International Convention (BIO USA),’ the world’s largest biopharmaceutical exhibition, scheduled to be held in Boston, USA, next month.